Strengthening the Genetic Testing Business Platform Through a Capital and Business Alliance with Hitachi High-Tech

「In addition, most recently, on 15 May 2017, we entered into a capital and business alliance agreement with Hitachi High-Technologies Corporation and strengthened our capital base. We also entered into an agreement on 27 August 2018, and raised funds through the issuance of new shares upon the exercise of third-party allotment stock acquisition rights. As a result, cash and deposits at the end of the third quarter amounted to ¥2,095 million, leaving our financial base stable.」

「Through recent fundraising, we entered into a capital and business alliance agreement with Hitachi High-Technologies Corporation on 15 May 2017 and strengthened our capital base. We also entered into an agreement on 27 August 2018, and raised funds through the issuance of new shares upon the exercise of third-party allotment stock acquisition rights. As a result, cash and deposits at the end of the consolidated fiscal year amounted to ¥1,845 million, leaving our financial base stable.」

「However, following our recent fundraising, we entered into a capital and business alliance agreement with Hitachi High-Technologies Corporation on 15 May 2017 and strengthened our capital base. We also entered into an agreement on 27 August 2018, and raised funds through the issuance of new shares upon the exercise of third-party allotment stock acquisition rights. As a result, cash and deposits at the end of the current third quarter of the consolidated fiscal year amounted to ¥2,351 million, leaving our financial base stable.」

「However, following our recent fundraising, we entered into a capital and business alliance agreement with Hitachi High-Technologies Corporation on 15 May 2017 and strengthened our capital base. We also entered into an agreement on 27 August 2018, and raised funds through the issuance of new shares upon the exercise of third-party allotment stock acquisition rights. As a result, cash and deposits at the end of the current second quarter of the consolidated fiscal year amounted to ¥2,291 million, leaving our financial base stable.」

「Most recently, on 15 May 2017, we entered into a capital and business alliance agreement with Hitachi High-Technologies Corporation and strengthened our capital base. As a result, cash and deposits at the end of the consolidated fiscal year amounted to ¥2,056 million, leaving our financial base stable.」

「In addition, on 15 May 2017 we entered into a capital and business alliance agreement with Hitachi High-Technologies Corporation. In addition to strengthening our capital base, we have been actively pursuing business expansion through sales partnerships and joint development. Accordingly, we have determined that no material uncertainty exists regarding the going-concern assumption.」

「As part of these measures, on 15 May 2017 we entered into a capital and business alliance with Hitachi High-Technologies Corporation and raised funds by issuing new shares to the company through a third-party allotment. Over the medium to long term, significant synergies are expected from combining our strength in providing automation system products with the company's broad-ranging cooperation in technology, manufacturing, sales networks and human resources.」

「The parties agreed that combining the management resources of the company and Hitachi High-Tech in the biotechnology-related fields would generate synergies and strengthen the relevant business fields. Accordingly, they entered into a business alliance covering the development and sale of fully automated genetic testing systems and reagents, and established a capital alliance to build a cooperative framework and ensure the effectiveness of the business alliance. “Hitachi High-Tech will sell the nucleic acid extraction system developed by the company and its reagents.” “Hitachi High-Tech will sell the compact genetic testing system developed by the company and its reagents.” “Using the technologies of the company and Hitachi High-Tech, Hitachi High-Tech will develop and sell a medium-sized genetic testing system. The reagents will be developed by the company and a third party and sold by Hitachi High-Tech.”」